Addex Therapeutics
ADXN
4 hedge funds and large institutions have $4.59M invested in Addex Therapeutics in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more ownership
Funds ownership: 0.05% → 0.05% (+0%)
77% less capital invested
Capital invested by funds: $20.4M → $4.59M (-$15.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.7K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
1
Caxton Corporation
Princeton,
New Jersey
| $2.4M | – | – | – |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $1.62M | – | – | – |
|
|
NLVP
3
New Leaf Venture Partners
New York
| $451K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $117K | +$2.7K | +14 | +2% |
|
ADXN Hedge Fund Activity: Q3 2021 in Review
4 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q3 2021, worth a combined $4.59M — down 77% from $20.4M a quarter earlier.
Fund positioning in ADXN was balanced in Q3 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $2.7K.
- 4 institutional investors held Addex Therapeutics (ADXN) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $4.59M of Addex Therapeutics stock for Q3 2021, down 77% quarter-over-quarter.
- 0 funds opened new Addex Therapeutics positions in Q3 2021 and 0 closed out.
- The largest Addex Therapeutics buyer in Q3 2021 was UBS Group, an estimated $2.7K added.
Based on aggregated 13F filings for Q3 2021.